SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement

SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement

Background: Current treatments for progressive neurodegenerative disorders characterized by cognitive impairment either have limited efficacy or are lacking altogether. SDI-118 is a small molecule which modulates the activity of synaptic vesicle glycoprotein 2A (SV2A) in the brain and shows cognitiv...

Full description

Bibliographic Details
Main Authors: Wouter Botermans, Michel Koole, Koen Van Laere, Jonathan R. Savidge, John A. Kemp, Stefan Sunaert, Maeve M. Duffy, Steven Ramael, Andrea M. Cesura, Kevin D’Ostilio, Denis Gossen, Torsten M. Madsen, Thomas Lodeweyckx, Jan de Hoon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Subjects:
randomized controlled trial
SDI-118
synaptic vesicle glycoprotein
SV2A
positron emission tomography
resting state functional MRI (rsfMRI)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1066447/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1066447/full

Similar Items